Correction to: Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era

Schreiber, Stefan; Ben-Horin, Shomron; Alten, Rieke; Westhovens, René; Peyrin-Biroulet, Laurent; Danese, Silvio; Hibi, Toshifumi; Takeuchi, Ken; Magro, Fernando; An, Yoorim; Kim, Dong-Hyeon; Yoon, SangWook; Reinisch, Walter

doi:10.1007/s12325-022-02082-9

Correction to: Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era

Correction
Published: 14 March 2022

Volume 39, page 2281, (2022)
Cite this article

Download PDF

Advances in Therapy Aims and scope Submit manuscript

Correction to: Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era

Download PDF

Stefan Schreiber¹,
Shomron Ben-Horin²,
Rieke Alten³,
René Westhovens⁴,
Laurent Peyrin-Biroulet^5,6,
Silvio Danese⁷,
Toshifumi Hibi⁸,
Ken Takeuchi⁹,
Fernando Magro^10,11,12,
Yoorim An¹³,
Dong-Hyeon Kim¹³,
SangWook Yoon¹³ &
…
Walter Reinisch¹⁴

1284 Accesses
1 Citation
Explore all metrics

The Original Article was published on 06 January 2022

Correction to: Adv Ther https://doi.org/10.1007/s12325-021-01990-6

In the original article, a few errors were introduced by the publisher during the typesetting process. The Graphical Abstract has been updated and a few minor formatting corrections have been made.

The original article has been corrected.

Author information

Authors and Affiliations

Department of Medicine I, Christian-Albrechts-University, University Hospital Schleswig-Holstein, Kiel, Germany
Stefan Schreiber
Gastroenterology Department, Sheba Medical Center, Tel Aviv University, Tel-Hashomer, Israel
Shomron Ben-Horin
Department of Internal Medicine II, Rheumatology, Clinical Immunology, Osteology, Schlosspark Klinik, University Medicine Berlin, Berlin, Germany
Rieke Alten
Department of Development and Regeneration, Skeletal Biology and Engineering Research Center, Leuven, Belgium
René Westhovens
Department of Gastroenterology, Nancy University Hospital, Vandoeuvre-les-Nancy, France
Laurent Peyrin-Biroulet
Inserm U1256 NGERE, Lorraine University, Vandoeuvre-les-Nancy, France
Laurent Peyrin-Biroulet
Gastroenterology and Endoscopy Unit, IRCCS Ospedale San Raffaele, University Vita-Salute San Raffaele, Milan, Italy
Silvio Danese
Center for Advanced IBD Research and Treatment, Kitasato Institute Hospital, Kitasato University, Tokyo, Japan
Toshifumi Hibi
Department of Gastroenterology, IBD Center, Tsujinaka Hospital Kashiwanoha, Chiba, Japan
Ken Takeuchi
Department of Biomedicine, Unit of Pharmacology and Therapeutics, Faculty of Medicine, University of Porto, Porto, Portugal
Fernando Magro
Department of Gastroenterology, Centro Hospitalar São João, Porto, Portugal
Fernando Magro
MedInUP, Centre for Drug Discovery and Innovative Medicines, Porto, Portugal
Fernando Magro
Celltrion Healthcare Co., Ltd, Incheon, Republic of Korea
Yoorim An, Dong-Hyeon Kim & SangWook Yoon
Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Währinger Gürtel 18-20, 1090, Vienna, Austria
Walter Reinisch

Authors

Stefan Schreiber
View author publications
You can also search for this author in PubMed Google Scholar
Shomron Ben-Horin
View author publications
You can also search for this author in PubMed Google Scholar
Rieke Alten
View author publications
You can also search for this author in PubMed Google Scholar
René Westhovens
View author publications
You can also search for this author in PubMed Google Scholar
Laurent Peyrin-Biroulet
View author publications
You can also search for this author in PubMed Google Scholar
Silvio Danese
View author publications
You can also search for this author in PubMed Google Scholar
Toshifumi Hibi
View author publications
You can also search for this author in PubMed Google Scholar
Ken Takeuchi
View author publications
You can also search for this author in PubMed Google Scholar
Fernando Magro
View author publications
You can also search for this author in PubMed Google Scholar
Yoorim An
View author publications
You can also search for this author in PubMed Google Scholar
Dong-Hyeon Kim
View author publications
You can also search for this author in PubMed Google Scholar
SangWook Yoon
View author publications
You can also search for this author in PubMed Google Scholar
Walter Reinisch
View author publications
You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Walter Reinisch.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schreiber, S., Ben-Horin, S., Alten, R. et al. Correction to: Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era. Adv Ther 39, 2281 (2022). https://doi.org/10.1007/s12325-022-02082-9

Download citation

Published: 14 March 2022
Issue Date: May 2022
DOI: https://doi.org/10.1007/s12325-022-02082-9

Use our pre-submission checklist

Avoid common mistakes on your manuscript.

Correction to: Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era

Correction to: Adv Ther https://doi.org/10.1007/s12325-021-01990-6

Author information

Authors and Affiliations

Corresponding author

Rights and permissions

About this article

Cite this article

Share this article

Search

Navigation